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BACKGROUND: Recently, low-molecular-weight heparins (LMWHs) were found to confer a survival advantage in cancer patients.
The mechanism underlying this observation is unclear, but may involve inhibition of tumour angiogenesis. We aimed to examine the
effects of nadroparin on tumour angiogenesis using a dorsal skinfold window chamber model in the Syrian hamster.
METHODS: AMel-3 and HAP-T1 tumours were grown in donor animals and fragments implanted in the window chambers. Animals
(N¼46) were treated with 200IU of nadroparin or saline for 10 days. Repeated intravital fluorescence microscopy was performed
to calculate functional microcirculatory parameters: number (N) and length (L) of microvessels, vascular area fraction (AF), and red
blood cell velocity (V). Microvessel density (MVD), fractal dimension, and pericyte coverage were assessed histologically.
RESULTS: Active angiogenesis was observed in control animals, resulting in a significant increase in N, L, and AF. In nadroparin-treated
animals, however, N and L did not increase whereas AF decreased significantly. Both groups showed an initial increase in V, but
nadroparin treatment resulted in an earlier decrease in red blood cell velocity over time. Compared with control animals, nadroparin-
treated animals showed a significantly lower MVD and fractal dimension but significantly higher pericyte coverage index (PCI).
CONCLUSIONS: Taken together, these results suggest that the LMWH nadroparin inhibits tumour angiogenesis and results
in microvessel normalisation.
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Cancer patients are at risk of venous thromboembolic events (VTEs)
induced by the hypercoagulable state associated with malignancy
(Mousa, 2004). There is therefore a clear rationale for prophylactic
administration of unfractionated heparin (UFH) or low-molecular-
weight heparin (LMWH) in these patients (Carrier and Agnes, 2009).
Recent clinical studies have suggested that, independent from its
effect on the incidence of VTE, heparin therapy might alter
survival in cancer patients (Kakkar et al, 2004; Klerk et al, 2005).
The potential anticancer mechanisms of LMWH administration
remain incompletely understood. Suggested targets include the
formation of cancer metastasis, cancer cell adhesion and invasion,
immune response, and angiogenesis (Smorenburg and Van
Noorden, 2001; Niers et al, 2007; Zacharski and Lee, 2008).
Angiogenesis is a critical process in survival, growth, and
metastasis of a malignant tumour, and is regulated by a number
of heparin-binding growth factors such as vascular endothelial
growth factor (VEGF) and basic fibroblast growth factor (bFGF).
These growth factors bind to heparane sulphate proteoglycans
(HSPGs) that are present in both the endothelial cells (ECs) and
the extracellular matrix (ECM). Binding of the receptors on the
endothelial wall results in proliferation and migration of ECs.
Soluble heparins have been shown to compete with angiogenic
growth factors for ECM binding sites, and UFH therapy increases
the plasma levels of certain growth factors (Folkman et al, 1989).
In contrast to UFH, LMWHs inhibit binding of heparin-binding
growth factors to their endothelial receptors, an effect that depends
on the molecule’s number of saccharide units (Norrby, 1993;
Norrby and Ostergaard, 1996). Fragments of o18 saccharides
inhibit the activity of VEGF, whereas fragments smaller than 10
saccharide units reduce bFGF activity (Soker et al, 1994). Similarly,
in an in vivo assay after intraperitoneal VEGF administration,
angiogenesis was suppressed by a 5-kDa but not by a 2.5- or
16.4-kDa heparin fraction (Norrby and Ostergaard, 1997).
Most of the experimental data on the anticancer effects of
heparins were generated by cell culture experiments. In vivo
microscopy (IVM) allows longitudinal noninvasive observation
of tumour angiogenesis in the living animal. In this study we
studied the effects of the LMWH nadroparin on tumour-associated
angiogenesis, using a dorsal skinfold window chamber model in
the Syrian golden hamster.
METHODS
The experimental protocol was approved by the animal experi-
mental ethical committee of the Ghent University, Ghent, Belgium.
Animals and tumour model
Male Syrian gold hamsters (Harlan, Horst, The Netherlands)
weighing 80–100g were housed separately in plastic cages with
free access to tap water and standard pellet food.
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animals) or HaP-T1 (nitrosamine-induced pancreatic cancer in
hamsters; 50% of the animals) cancer cell lines were cultured and
1 million cells suspended in 0.1ml of saline were injected
subcutaneously in the proximal hind leg of donor hamsters. When
tumours reached a size of 10mm
3 (usually after 2–3 weeks), four
tumour fragments (±0.5–1mm
2) were implanted in the window
chamber of acceptor animals at 24h after dorsal skinfold window
chamber implantation.
Dorsal skinfold window chamber implantation
Hamsters were anaesthetised with intraperitoneal injection of
ketamine (Ketalar, Pfizer, Elsene, Belgium) and xylazin (Rompun,
Bayer, Diegem, Belgium) and placed on a heating pad. The
procedure is described in detail by Endrich et al (1980) and
Menger et al (2002). In brief, a titanium frame is surgically fixed
onto a dorsal skinfold of the animal. On one side of the skinfold, a
circular area of dermis and subcutis is surgically removed (15mm
diameter) and covered by a circular cover glass. Animal were
housed separately and were allowed to recover for 24h from
surgery and anaesthesia before tumour fragment implantation.
Window chambers were inspected daily for the presence of air
bubbles, inflammation, infection, or vascular thrombosis.
Experimental therapy
Animals (N¼23 per group) were treated with daily subcutaneous
injections of either 0.07ml of saline or 200IU aXa of nadroparin
(Fraxiparine, GSK, Genval, Belgium) dissolved in 0.07ml of saline.
Injections started the day before tumour implantation.
Intravital microscopy
In vivo fluorescence microscopy was performed on days 0 (day of
tumour implantation), 3, 6, and 9. Unconscious animals (keta-
mine/xylazin anaesthesia) received an i.v. bolus of 0.1ml of
fluorescein isothiocyanate (FITC)–labelled dextran (20mgml
–1)
(Sigma-Aldrich NV, Bornem, Belgium) and were placed on the
stage of a modified Olympus BX51WI microscope (Olympus NV,
Aartselaar, Belgium). Fluorescence microscopy was performed
using an HBO 50W mercury lamp (Osram, Zaventem, Belgium)
and a FITC filter set (excitation filter 460–490nm) for detecting
epifluorescent intravascular plasma. Static and dynamic images of
the microcirculation were obtained in four different regions in
each chamber. Digital images were captured real time on the hard
disc of a computer using a high sensitivity digital camera (model
C8484-05, Hamamatsu Photonics, Hamamatsu, Japan). Quantita-
tive microcirculatory analysis was performed using a software
package (CapImage, H Zeintl Engineering, Heidelberg, Germany).
The following parameters were calculated: microvessel length per
area (LA; cmcm
–2), number of microvessels per high-power field
(NA; n/HPF  20), vascular area fraction (AF; %), and microvessel
diameter (D; mm). In addition, centreline red blood cell velocity
(V;m ms
–1) was measured by analysing 10 microvessels per region
of interest, randomly chosen among those that crossed a vertical
line drawn over the centre of the computer screen, as described
by Laschke et al (2005). Volumetric blood flow (VQ; pls
–1)
was calculated from V and D as VQ¼p (D/2)
2 V/K, in which
K (¼1.3) represents the Baker–Wayland factor (Baker and
Wayland, 1974), and considers the parabolic velocity profile of
blood in microvessels. Functional capillary density was not
calculated as angiogenic sprouts and buds contain red blood cells
without a measurable perfusion and therefore this parameter does
not accurately reflect tumour angiogenesis (Torres et al, 1995).
On day 9 after implantation of the tumour fragments, animals
were killed and the tissue inside the observation chambers was
excised for histology. Tissue fragments were fixed in 10% formalin,
embedded in paraffin, and 4mm thick sections were cut and
mounted for immunohistochemistry.
Immunohistochemistry
Factor VIII (von Willebrand factor, FVIII) immunostaining was
used to visualise tumour microvessels and calculate microvessel
density (MVD), whereas a-smooth muscle actin (aSMA) was used
to identify pericytes and calculate the pericyte coverage index
(PCI) as a measure of microvessel maturation.
Serial tissue sections were deparaffinised in xylene, hydrated
by serial immersion in ethanol, and subsequently incubated in
Proteinase K (Dako, Heverlee, Belgium) for antigen retrieval.
Endogenous peroxidase activity was blocked with 3% H2O2 in
methanol. Slides were washed in Tris-buffered saline (TBS)–
Tween and treated with UltraSens Block RTU (ImmunoLogic,
Duiven, The Netherlands) to inhibit nonspecific antibody binding.
Sections were incubated with mouse monoclonal antibodies
against FVIII (Dako) or aSMA (Abcam, Cambridge, UK) at room
temperature for 1h, rinsed in TBS–Tween, and incubated with
secondary antibodies (UltraSens Biotinylated Goat Anti-polyvalent
RTU; ImmunoLogic) followed by streptavidin peroxidase (Ultra-
Sens Streptavidin Peroxidase RTU; ImmunoLogic) for 10min each.
Visualisation of the immunoprecipitate was performed by adding
3,30-diaminobenzidine (Biogenex, San Ramon, CA, USA) and
counterstaining with haematoxylin. Positive and negative controls
were processed simultaneously.
Serial FVIII and aSMA-stained sections of dorsal skinfold tissue
were entirely scanned for tumour regions (magnification  20)
and digitised. Microvessel density was calculated by digital image
analysis using the NIH ImageJ software (version 1.39s, available
from http://rsb.info.nih.gov/ij). Using the threshold colour plugin,
FVIII- and aSMA-positive cells were isolated from background
staining and the resulting images converted to binary. Microvessel
density was calculated using the ratio of black pixels over the total
number of pixels in the binary image, whereas the PCI was
calculated as the ratio of aSMA-positive pixels vs FVIII-positive
pixels. The fractal dimension of the microvessel bed was calculated
using the ImageJ FracLac plugin. The fractal dimension is a
rational number between 1 and 2 (the dimensions of a line and
plane, respectively), and has been shown to correlate with the
degree of branching, tortuosity, and irregularity of the tumour-
associated microvascular network (Dey, 2005).
Statistical analysis
Data are expressed as mean±s.d. or median (interquartile range).
Differences were analysed using Student’s t-test or Mann–Whitney
rank-sum test where appropriate. Results were considered
statistically significant when the probability of a type I error was
p5%. Statistical analysis was performed with SigmaStat 11.0
(Systat Software, Richmond, CA, USA).
RESULTS
All animals (N¼46) developed 2–4 macroscopically visible
tumours in the observation window, indicating appropriate
angiogenesis and viability (Figure 1). As both the dynamic in vivo
microscopic results and histology parameters with the exception of
the PCI did not differ between the HaP-T1 cell line and the AMel-3
cell line (data not shown), statistical analyses were performed on
the combined group. Five animals were excluded on the first day of
observation because of insufficient optical quality of the window
chamber. In all other animals (N¼41), the skinfold chamber
provided excellent image quality and resolution over the duration
of the experiment (9 days).
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The microvascular parameters derived from in vivo microscopic
observations are summarised in Figure 2 and Table 1. In control
animals (N¼20), the number of microvessels and the vascular
area fraction increased significantly whereas a nonsignificant
increase in vessel length was observed. In nadroparin-treated
animals (N¼21), however, vessel length and number of micro-
vessels did not change significantly over time whereas a significant
decrease in vascular area fraction was noted.
Effects of nadroparin on the dynamic properties of the
tumour vascular bed
The results of microcirculatory calculations are summarised in
Figure 3 and Table 2. In both groups, microvessel diameter
increased significantly over time, although in the nadroparin
group the increase in diameter between days 6 and 9 was less
pronounced. The evolution of microvessel RBC velocity is depicted
in Figure 3B. In the control group, velocity increased progressively
until day 6, followed by a significant decline at day 9. In the
experimental group, however, RBC velocity peaked earlier (day 3)
and subsequently stabilised at a lower value. Volumetric blood
Figure 1 Representative tumour growth and angiogenesis observed for
9 days in a control animal (A–D) and a nadroparin-treated animal (E–H).
The difference in microvessel density is clearly visible, as is the higher
number of neovascular buds and sprouts in the control animal (image D).
Scale bar¼100mm.
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Figure 2 Vessel length (A), number of microvessels per area (B), and
vascular area fraction (C) in control and nadroparin-treated animals for 9
days.
Table 1 Evolution of microvessel length, number, and area fraction over time
Day 0 Day 3 Day 6 Day 9
Control (N¼20)
L (cmcm
–2) 61.8±41 65.9±21 65.2±32 76.0±74
N( ncm
–2) 216.8±80 280.8±108* 270.3±107* 340.2±105**
VAF (%) 22.4±6.3 20±6.4* 19.7±6.5* 25.6±8.4**
Nadroparin (N¼21)
L (cmcm
–2) 65.4±57 67.2±23 61.8±31 66.5±54
N( ncm
–2) 226.8±80 222.2±86*** 179.4±77*
,*** 238.9±87***
VAF (%) 23.8±6.7 19.2±7.4* 17.8±5.0*
,*** 15.6±6.9**
,***
Abbreviations: L¼microvessel length; N¼number of microvessels; VAF¼vascular
area fraction. *Po0.05 vs day 0. **Po0.05 vs day 0, 3 and 6. ***Po0.05 vs untreated
animals at corresponding time points. Data represent mean±s.d.
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nadroparin-treated animals show an early peak on day 3, followed
by stable readings until the end of the experiment.
Immunohistochemical analysis
Histological examination of the dissected dorsal skinfolds on day 9
after tumour fragment implantation showed macroscopically vital
tumour tissue in all animals. Microvessel quantitative and
morphology data are illustrated in Figure 4. The microvessel
density (FVIII staining) was 11.1% (6.2–18.1) in the control group
and 4.5% (1.8–9.1) in the nadroparin-treated group (Po0.001,
Mann–Whitney U-test). Fractal dimension was significantly
higher in control animals than in nadroparin-treated animals
(1.5 (1.3–1.6) and 1.4 (1.3–1.5), respectively, P¼0.029, Mann–
Whitney U-test).
Data concerning microvessel maturation are depicted in
Figure 5. The PCI was 73.6% (39.1–108.5) in untreated animals
and 96.8% (74.3–126.1) in nadroparin-treated animals (P¼0.012,
Mann–Whitney U-test). The difference in PCI between control and
nadroparin-treated animals was more pronounced when the
HaPT-1 cell line was used (Table 3).
DISCUSSION
The results from recent clinical studies in advanced cancer patients
have led to increasing interest in the effects of heparins on tumour
growth. Klerk et al (2005) randomised advanced or metastatic
cancer patients to either 6 weeks of nadroparin or placebo, and
found a significant overall survival benefit in favour of nadroparin
therapy (hazard ratio of mortality 0.75; 95% CI 0.59–0.96).
The underlying mechanisms by which heparins inhibit tumour
progression are incompletely understood, and may include
inhibition of selectin-mediated cellular adhesion, inhibition of
tumour invasion, and induction of cancer cell apoptosis (Smoren-
burg and Noorden, 2001; Niers et al, 2007; Lee, 2007).
One of the causal pathways under scrutiny is the inhibition of
tumour-associated angiogenesis. Most in vivo angiogenesis assays,
such as the mouse cremaster muscle or rat mesenteric window
model, allow to observe the microcirculation only once after
therapy (Norrby, 2000; Wan et al, 2001). The dorsal skinfold
chamber model allows noninvasive detailed and repetitive analysis
of tumour microvascular properties (Torres et al, 1995). Our study
is the first to use repetitive observation in a dorsal skinfold
window chamber model to assess the effects of an LMWH on
tumour-associated angiogenesis in an immunocompetent animal
model.
Our results suggest that nadroparin exerts an anti-angiogenic
effect in vivo, as evidenced by a significantly lower vascular area
fraction and MVD when compared with control animals. More-
over, nadroparin-treated tumours showed signs of microvessel
normalisation, including a smaller increase in diameter, a higher
PCI, and less vessel tortuosity (smaller fractional dimension).
Vessel normalisation is a well-characterised early phenotypic effect
of anti-angiogenic therapy (Fukumura and Jain, 2008). The
difference in vessel diameter and tortuosity may explain the
decrease in vascular area fraction over time in nadroparin-treated
animals despite the fact that both vessel length and vessel number
did not change appreciably over time in this group.
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Figure 3 Microvessel diameter (A), red blood cell velocity (B),
and volumetric blood flow (C) in control and nadroparin-treated animals
for 9 days.
Table 2 Evolution of microvessel diameter, red blood cell velocity, and
volumetric blood flow over time
Day 0 Day 3 Day 6 Day 9
Control (N¼20)
D( mm) 21.2±16.1 23.1±8.1 23.8±9.3 26.5±12.8*
V( m ms
–1) 0.3±0.1 0.4±0.1* 0.4±0.2* 0.3±0.1**
VQ (pls
–1) 163.1±159 135.8±67* 151.6±108* 171.5±158*
Nadroparin (N¼21)
D( mm) 21.6±10.1 22.5±7.9 24.2±7.1* 24.4±8.0*
V( m ms
–1) 0.4±0.1*** 0.5±0.2 0.4±0.1 0.4±0.1***
VQ (pls
–1) 130.4±122*** 161.7±118 151.9±102 156.8±120*
Abbreviations: D¼microvessel diameter; V¼red blood cell velocity; VQ¼volu-
metric blood flow; Data represent mean±s.d. *Po0.05 vs day 0. **Po0.05 vs days 3
and 6. ***Po0.05 vs untreated animals at corresponding time points.
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Figure 4 Microvessel density (FVIII staining) and fractal dimension in control and nadroparin-treated animals. (A, B) Examples of FVIII-stained
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effects of LMWHs have used physiological angiogenesis models
such as the rat mesentery or matrigel plug assays. Mousa and
Mohamed (2004) showed that the LMWH tinzaparin inhibits
angiogenesis in the chick chorioallantoic membrane model by
upregulation of the tissue factor pathway inhibitor. Tissue factor,
which is the initiator of the extrinsic coagulation pathway, is
expressed by many cancer types and was shown to promote
tumour angiogenesis through protease-activated receptor 2 (PAR-2)
signalling (Belting et al, 2004). Similarly, Marchetti et al (2008)
showed that the LMWHs, enoxaparin and dalteparin, but not
unfractionated heparin, significantly inhibited capillary tube
formation in a Matrigel assay. Interestingly, the anti-angiogenic
potential of LMWHs seems to be depending on the size of the
molecule and number of saccharide units. Khorana et al (2003)
showed that molecules with a weight in the range of 3–6kDa or
48 saccharide units maximally inhibited angiogenesis in a
Matrigel assay. Similar findings were reported by Norrby (2000),
who showed that 2.5–5kDa heparin fragments maximally
suppressed VEGF-induced angiogenesis in a rat mesenteric
window assay. As the molecular weight of nadroparin is
approximately 4.5kDa, our data confirm the anti-angiogenic
potential of heparin fragments within the above-mentioned range.
The basic mechanisms underlying the anti-angiogenic effect of
the LMWHs remain to be elucidated. Several potential pathways
have been proposed. First, LMWHs suppress TF gene expression
and enhance the release of TF pathway inhibitor (Mousa and
Mohamed, 2000; Schultz et al, 2001). Second, heparin fragments
smaller than 18 saccharide units were shown to interfere with the
binding of VEGF to its cellular receptor (Soker et al, 1994). In
addition, heparins inhibit the release of heparanase by malignant
tissue (Parish et al, 1999, 2001). Heparanase not only creates a pro-
angiogenic environment through the release of heparin-bound
growth factors (VEGF, bFGF) from the interstitial matrix and
upregulation of TF and VEGF expression, but is also a key enzyme
in the degradation of this matrix, which renders it ‘permissive’ for
neovascular outgrowth (El-Assal et al, 2001; Wood et al, 2005).
Indeed, Collen et al (2000) found that structural alterations of the
fibrin matrix induced by LMWH reduced the invasion of capillary-
forming ECs. Nadroparin may exert a similar effect on ECM
properties, as Barner et al (1987) found that in vitro, LMWH with a
mean weight of 4.5kDa inhibited 99% of heparanase activity.
In addition to a decrease in the number of microvessels, several
other structural effects were found to result from nadroparin
administration in this study. It is noteworthy that microvascular
diameter at day 9 was significantly smaller compared with control
animals. Theoretically, this may be explained by the inhibition
bFGF and PDFG activity, which both exert a vasodilatory activity
(Pukac et al, 1997; Takase et al, 1999; Millette et al, 2005).
The higher PCI and more efficient perfusion that we found in
nadroparin-treated animals suggest a normalising effect of this
LMWH on the tumour’s vascular bed. As a consequence, there may
be a role for LMWH to enhance drug delivery of concurrently
administered cytotoxic therapy. In patients with pancreatic cancer
and small cell lung cancer, administration of LMWH enhanced the
efficacy of combined chemotherapy (Icli et al, 2002; Altinbas et al,
2004).
Several limitations apply to the interpretation of the current
results. First, although it may be assumed that inhibition of
tumour angiogenesis in this model translates into inhibition of
tumour growth, this could not be assessed because of the short
time frame used (9 days). Second, implantation of window
chambers invariably induces a certain degree of inflammation
that might confound the findings related to tumour angiogenesis.
Finally, it is unclear to what extent findings in a heterotopic animal
tumour model will translate into relevant clinical effects in
patients.
In addition to the uncertain basic mechanisms by which
heparins interfere with tumour angiogenesis, several other
questions remain open. It is unclear whether the anti-angiogenic
effects of LMWHs depend only on their molecular weight and
number of saccharide units, or also on other physicochemical
properties such as manufacturing process and degree of sulpha-
tion. In addition, although most of the mechanisms shown thus far
suggest a rather generic mode of action, preclinical studies suggest
that the antitumour effects of heparins depend on the cancer cell
type (Niers et al, 2009). Finally, the LMWH dose and duration in
the clinical setting remain to be determined.
In conclusion, nadroparin inhibits tumour-associated angio-
genesis and normalises microvessel structure in this immuno-
competent tumour model using the dorsal skinfold chamber.
Further study is required to determine whether direct effects on
EC proliferation and modelling, changes in the structure of the
extracellular matrix, or both explain our observations.
REFERENCES
Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, Cetin M, Soyuer S
(2004) A randomized clinical trial of combination chemotherapy with
and without low-molecular-weight heparin in small cell lung cancer.
J Thromb Haemost 2: 1266–1271
Baker M, Wayland H (1974) On-line volume flow rate and velocity profile
measurements for blood in microvessels. Microvasc Res 7: 131–143
Barner M, Eldor A, Wasserman L, Matzner Y, Cohen IR, Fuks Z, Vlodavsky I
(1987) Inhibition of heparanase-mediated degradation of extracellular-matrix
heparan-sulfate by non-anticoagulant heparin species. Blood 70: 551–557
Belting M, Dorrell MI, Sandgren S, Aguilar E, Ahamed J, Dorfleutner A,
Carmeliet P, Mueller BM, Friedlander M, Ruf W (2004) Regulation of
angiogenesis by tissue factor cytoplasmic domain signaling. Nature Med
10: 502–509
Carrier M, Agnes YY (2009) Prophylactic and therapeutic anticoagulation
for thrombosis-major issues in oncology. Nat Clin Pract Oncol 6:
74–84
Collen A, Smorenburg SM, Peters E, Lupu F, Koolwijk P, Van Noorden C,
van Hinsbergh VWM (2000) Unfractionated and low molecular weight
heparin affect fibrin structure and angiogenesis in vitro. Cancer Res 60:
6196–6200
Dey P (2005) Basic principles and applications of fractal geometry in
pathology. Anal Quant Cytol Histol 27: 284–290
El-Assal ON, Yamanoi A, Ono T, Kohno H, Nagasue N (2001) The
clinicopathological significance of heparanase and basic fibroblast
growth factor expressions in hepatocellular carcinoma. Clin Cancer Res
7: 1299–1305
Table 3 Immunohistochemistry results
Group Control (N¼20) Nadroparin (N¼21) P-value
AMel-3
FVIII 9.4 (5.2–15.1) 3.8 (1.4–6.6) o0.001
SMA 5.1 (3.8–8.0) 1.7 (1.4–7.9) 0.020
PCI (%) 95.7 (54.5–117.9) 111.8 (63.3–134.3) NS
HaP-T1
FVIII 11.7 (6.9–19.9) 5.8 (2.4–10.7) o0.001
SMA 10.9 (7.4–17.2) 5.8 (2.6–10.4) o0.001
PCI (%) 76.5 (39.7–111.7) 108.3 (80.2–157.8) 0.003
Abbreviations: FVIII¼factor VIII staining; SMA¼smooth muscle antigen staining;
PCI¼pericyte coverage index. Data represent median (interquartile range).
Nadroparin and angiogenesis
I Debergh et al
842
British Journal of Cancer (2010) 102(5), 837–843 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sEndrich B, Asaishi K, Gotz A, Messmer K (1980) Technical report – a new
chamber technique for microvascular studies in unanesthetized
hamsters. Res Exp Med 177: 125–134
Folkman J, Weisz PB, Joullie MM, Li WW, Ewing WR (1989) Control of
angiogenesis with synthetic heparin substitutes. Science 243: 1490–1493
Fukumura D, Jain R (2008) Imaging angiogenesis and the microenviron-
ment. APMIS 116: 695–715
Icli F, Akbulut H (2002) Low molecular weight heparin (LMWH) increases
the efficacy of cisplatinum plus gemcitabine combination in advanced
pancreatic cancer. 38th Annual Meeting of the American Society of
Clinical Oncology Fl: Wiley-Liss, pp 507–512
Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin
G, Thomas M, Quigley M, Williamson RCN (2004) Low molecular weight
heparin, therapy with dalteparin, and survival in advanced cancer: the
fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol
22: 1944–1948
Khorana AA, Sahni A, Altland OD, Francis CW (2003) Heparin inhibition
of endothelial cell proliferation and organization is dependent on
molecular weight. Arteriosclers Thromb Vasc Biol 23: 2110–2115
Klerk CPW, Smorenburg SM, Otten HM, Lensing AWA, Prins MH, Piovella
F, Prandoni P, Bos MMEM, Richel DJ, van Tienhoven G, Buller HR
(2005) The effect of low molecular weight heparin on survival in patients
with advanced malignancy. J Clin Oncol 23: 2130–2135
Laschke MW, Elitzsch A, Vollmar B, Menger MD (2005) In vivo analysis of
angiogenesis in endometriosis-like lesions by intravital fluorescence
microscopy. Fertil Steril 84: 1199–1209
Lee A (2007) The effects of low molecular weight heparins on venous
thromboembolism and survival in patients with cancer. Thromb Res 120:
S121–S127
Marchetti M, Vignoli A, Russo L, Balducci D, Pagnoncelli M, Barbui T,
Falanga A (2008) Endothelial capillary tube formation and cell
proliferation induced by tumor cells are affected by low molecular
weight heparins and unfractionated heparin. Thromb Res 121: 637–645
Menger M, Laschke M, Vollmar B (2002) Viewing the microcirculation
through the window: some twenty years experience with the hamster
dorsal skinfold chamber. Eur Surg Res 34: 83–91
Millette E, Rauch BH, Defawe O, Kenagy RD, Daum G, Clowes AW (2005)
Platelet-derived growth Factor-BB-induced human smooth muscle cell
proliferation depends on basic FGF release and FGFR-1 activation.
Circ Res 96: 172–179
Mousa S (2004) Low-molecular-weight heparin in thrombosis and cancer.
Semin Thromb Hemost 30: 25–30
Mousa SA, Mohamed S (2000) Anti-angiogenic efficacy & mechanism of the
low molecular weight heparin (LMWH), Tinzaparin and tissue factor
pathway inhibitor (TFPI): potential anti-cancer link and benefits. Blood
96: 182b
Mousa SA, Mohamed S (2004) Inhibition of endothelial cell tube formation
by the low molecular weight heparin, tinzaparin, is mediated by tissue
factor pathway inhibitor. Thromb Haemos 92: 627–633
Niers TMH, Bruggemann LW, Klerk CPW, Muller FJM, Buckle T, Reitsma
PH, Richel DJ, Spek CA, Van Tellingen O, Van Noorden CJF (2009)
Differential effects of anticoagulants on tumor development of mouse
cancer cell lines B16, K1735 and CT26 in lung. Clin Exp Metastasis
26: 171–178
Niers TMH, Klerk CPW, DiNisio M, Van Noorden CJF, Buller HR, Reitsma
PH, Richel DJ (2007) Mechanisms of heparin induced anti-cancer activity
in experimental cancer models. Crit Rev Oncol Hematol 61: 195–207
Norrby K (1993) Heparin and angiogenesis: a low-molecular-weight
fraction inhibits and a high-molecular-weight fraction stimulates
angiogenesis systemically. Haemostasis 23: 141–149
Norrby K (2000) 2.5 and 5.0kDa heparin fragments specifically inhibit
microvessel sprouting and network formation in VEGF(165)-mediated
mammalian angiogenesis. Int J Exp Pathol 81: 191–198
Norrby K, Ostergaard P (1996) Basic-fibroblast-growth-factor-mediated
de novo angiogenesis is more effectively suppressed by low-molecular-
weight than by high-molecular-weight heparin. Int J Microcirc Clin Exp
16: 8–15
Norrby K, Ostergaard P (1997) A 5.0kDa heparin fraction systemically
suppresses VEGF (165)-mediated angiogenesis. Int J Microcirc Clin Expl
17: 314–321
Parish CR, Freeman C, Brown KJ, Francis DJ, Cowden WB (1999)
Identification of sulfated oligosaccharide-based inhibitors of tumor
growth and metastasis using novel in vitro assays for angiogenesis and
heparanase activity. Cancer Research 59: 3433–3441
Parish CR, Freeman C, Hulett MD (2001) Heparanase: a key enzyme
involved in cell invasion. Biochimica Et Biophysica Acta-Reviews on
Cancer 1471: M99–M108
Pukac LA, Carter JE, Ottlinger ME, Karnovsky MJ (1997) Mechanisms of
inhibition by heparin of PDGF stimulated MAP kinase activation in
vascular smooth muscle cells. J Cell Physiol 172: 69–78
Schultz C, Ma Q, Fu S, Ahmad S, Hoppensteadt DA, Fareed J (2001)
Differential anticoagulant effects of three different low-molecular-weight
heparins: assay-dependence and release of tissue factor pathway
inhibitor. Clin Chem 47: A169
Smorenburg S, Noorden CV (2001) The complex effects of heparins on
cancer progression and metastasis in experimental studies. Pharmacol
Rev 53: 93–105
Smorenburg SM, Van Noorden CJF (2001) The complex effects of heparins
on cancer progression and metastasis in experimental studies. Pharmacol
Rev 53: 93–105
Soker S, Goldstaub D, Svahn CM, Vlodavsky I, Levi BZ, Neufeld G (1994)
Variations in the size and sulfation of heparin modulate the effect of
heparin on the binding of Vegf(165) to its receptors. Biochem Biophys
Res Comm 203: 1339–1347
Takase H, Oemar BS, Pech M, Luscher TF (1999) Platelet-derived growth
factor-induced vasodilatation in mesenteric resistance arteries by nitric
oxide: blunted response in spontaneous hypertension. J Cardiovasc
Pharmacol 33: 223–228
Torres IP, Hartleyasp B, Borgstrom P (1995) Quantitative angiogenesis in a
syngeneic tumor spheroid model. Microvasc Res 49: 212–226
Wan MX, Zhang XW, Torkvist L, Thorlacius H (2001) Low molecular
weight heparin inhibits tumor necrosis factor alpha-induced leukocyte
rolling. Inflammation Res 50: 581–584
Wood RJ, Parish CR, Hulett MD (2005) The pro-inflammatory enzyme
heparanase binds the CIMPR (CD222) in a M6P independent manner and
promotes cell invasion by degrading the ECM. Tissue Antigens 66: 592
Zacharski LR, Lee AYY (2008) Heparin as an anticancer therapeutic.
Expert Opin Investig Drugs 17: 1029–1037
Nadroparin and angiogenesis
I Debergh et al
843
British Journal of Cancer (2010) 102(5), 837–843 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s